• Substantial extension of financial runway visibility into December 2022
• Financing availability secured for initiation of NOX-A12 Phase 2/3 in Glioblastoma
and Phase 2 in Pancreatic Cancer, both on track to start in Q3 2022
Berlin, 3 January 2022. Eckert & Ziegler has acquired 100% of the shares of Argentinian nuclear medicine specialist Tecnonuclear S. A., a manufacturer of Technetium-99 generators and a portfolio of related biomolecules. These so-called "cold kits"…
Berlin, Germany, December 20, 2021 – Berlin Startup Newsenselab is rounding out a year of successes with their most recent financing round. Headlining the list of achievements is “M-sense Migräne”, a digital health application (DiGA) eligible to be…
Cardiovascular conditions affect life in the intestines. But the opposite is also true: Bacteria in the gut influence the course of cardiovascular disease. A team led by MDC researcher Sofia Forslund reports in Nature on the opportunities and risks…
How much tissue-specific information is contained in enhancer sequences?
Lindera – one of the leading deep-tech companies in the field of computer vision – has successfully closed a Series A financing round. The Berlin-based health-tech company is receiving additional growth capital from new investors as well as from…
Plant-based egg alternative made in Germany closes first funding round with leading AgriFood investors from around the globe
The prognosis for pancreatic cancer is usually grim: The tumors are often detected too late and are then difficult to treat. Yet a small percentage of patients survive many years after diagnosis. Scientists from the Berlin Institute of Health at…
In the case of serious soft tissue injuries, tissue transplantation is sometimes unavoidable. For the patient, however, this means a serious intervention. In the future, the missing tissue could grow directly in the patient's body - in isolation…
TOKYO and Hennigsdorf, Germany, November 15, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pantherna Therapeutics GmbH (CEO: Klaus Giese, Ph.D., “Pantherna”) today announced that the companies have…
